Please assess the completion status of the following clinical trial:

Trial Title: High Dose Vitamin D vs Standard Dose Vitamin D Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All participants must be female and at least 21 years of age~* Signed informed consent~* Patients must have had histologically confirmed stage I-III breast carcinoma that is positive for Estrogen Receptor (ER) and/or Progesterone Receptor (PR).~* Post-menopausal~* Beginning adjuvant aromatase inhibitor therapy, with no previous use within the last 6 weeks~* Bisphosphonates are allowed at the treating investigator¡¦s discretion~* Performance status (WHO/ECOG scale) 0-2.~Exclusion Criteria:~* History of kidney stones~* Hypercalcemia at baseline, defined as any corrected calcium greater than the laboratory's normal parameters~* History of either symptomatic hypercalcemia or hyperparathyroidism, at the treating investigator's discretion~* Baseline Vitamin D level greater than 50 ng/mL~* Inability or unwillingness to comply with, or follow study procedures.~* Currently taking Phenytoin or phenobarbital -7 Currently taking cholestyramine or orlistat~* Malabsorption syndrome, such as Crohn's disease~Prohibited Therapies: Patients may not take additional Calcium and Vitamin D aside from the study medications. Patients who are on cholestyramine or orlistat will not be allowed on the trial. Also, patients who are taking phenytoin or phenobarbital are not allowed on the trial either because of interaction between Vitamin D and anti-epileptic medications.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High Dose Vitamin D ARM (Type: EXPERIMENTAL): 50,000 IU Vitamin D supplement
- 800 IU Vitamin D Supplement (Type: ACTIVE_COMPARATOR): 800 IU Vitamin D Supplement

Based on this trial design, predict the completion outcome and termination type (if applicable).